A day after announcing an agreement with a Chinese firm to develop and commercialize a new drug cocktail treatment for chronic hepatitis C, TaiGen Biopharmaceuticals Holdings Ltd (太景醫藥研發控股) provided more details of the link-up.
TaiGen and YiChang HEC ChangJiang Pharmaceutical Co Ltd (HEC, 宜昌東陽光長江藥業) have agreed to establish a joint venture to produce a treatment cocktail of two oral direct-acting antiviral agents (DAA) — TaiGen’s furaprevir (TG-2349), a NS3/4A protease inhibitor, and HEC’s yimitasvir (DAG-181), a NS 5 protein inhibitor.
The joint venture is to be established before the end of this year with capitalization of 680 million yuan (US$102 million), of which 348.4 million yuan would be provided by HEC in cash in exchange for a 51 percent stake.
TaiGen will receive a 49 percent stake for its licensing rights to TG-2349, which is appraised at about US$50 million, company officials said yesterday at a news conference in Taipei.
The company is expecting to book profits of US$20 million for its 49 percent stake before the second half of next year, TaiGen vice president of finance Richard Lu (呂理堅) said.
The agreement also stipulates that when the new cocktail completes its second-phase clinical trials in China, TaiGen would sell a 9 percent-portion of its stake in the joint venture to HEC for about another US$40 million, Lu added.
However, the conditions for the US$40 million sale would be contingent upon whether the new cocktail is able to achieve a sustained viral response rate of more than 90 percent in its second-phase study, Lu said.
The new cocktail has received fast-track review designation from Chinese regulators, and is scheduled to hit the market in two to three years, TaiGen chief operating officer Hsu Ming-chu (許明珠) said.
The outcome of scientific due diligence and animal testing on drug-to-drug interactions combining TG-2349 and DAG-181 have been favorable, Hsu said.
“We were approached by HEC last May to explore a partnership and we found the company to be a capable partner in terms of funding as well as the viability of its new drug,” Hsu said, adding that TaiGen had rejected a number of prospective candidates.
The joint venture will allow TaiGen to begin commercializing new drugs earlier in the development phase. In the past its revenue streams came from out-licensing its late-stage development drugs.
Currently available DAA treatments for hepatitis C can cost as much as US$90,000 for a 12-week regimen, but the joint venture’s new drug would be priced significantly lower, Hsu said.
The lower pricing, and the enlisting of a Chinese partner represent an advantage in gaining approval from Beijing regulators, who are looking to control China’s healthcare costs and improve access to treatments, Hsu said.
Stephen Garrett, a 27-year-old graduate student, always thought he would study in China, but first the country’s restrictive COVID-19 policies made it nearly impossible and now he has other concerns. The cost is one deterrent, but Garrett is more worried about restrictions on academic freedom and the personal risk of being stranded in China. He is not alone. Only about 700 American students are studying at Chinese universities, down from a peak of nearly 25,000 a decade ago, while there are nearly 300,000 Chinese students at US schools. Some young Americans are discouraged from investing their time in China by what they see
MAJOR DROP: CEO Tim Cook, who is visiting Hanoi, pledged the firm was committed to Vietnam after its smartphone shipments declined 9.6% annually in the first quarter Apple Inc yesterday said it would increase spending on suppliers in Vietnam, a key production hub, as CEO Tim Cook arrived in the country for a two-day visit. The iPhone maker announced the news in a statement on its Web site, but gave no details of how much it would spend or where the money would go. Cook is expected to meet programmers, content creators and students during his visit, online newspaper VnExpress reported. The visit comes as US President Joe Biden’s administration seeks to ramp up Vietnam’s role in the global tech supply chain to reduce the US’ dependence on China. Images on
New apartments in Taiwan’s major cities are getting smaller, while old apartments are increasingly occupied by older people, many of whom live alone, government data showed. The phenomenon has to do with sharpening unaffordable property prices and an aging population, property brokers said. Apartments with one bedroom that are two years old or older have gained a noticeable presence in the nation’s six special municipalities as well as Hsinchu county and city in the past five years, Evertrust Rehouse Co (永慶房產集團) found, citing data from the government’s real-price transaction platform. In Taipei, apartments with one bedroom accounted for 19 percent of deals last
US CONSCULTANT: The US Department of Commerce’s Ursula Burns is a rarely seen US government consultant to be put forward to sit on the board, nominated as an independent director Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), the world’s largest contract chipmaker, yesterday nominated 10 candidates for its new board of directors, including Ursula Burns from the US Department of Commerce. It is rare that TSMC has nominated a US government consultant to sit on its board. Burns was nominated as one of seven independent directors. She is vice chair of the department’s Advisory Council on Supply Chain Competitiveness. Burns is to stand for election at TSMC’s annual shareholders’ meeting on June 4 along with the rest of the candidates. TSMC chairman Mark Liu (劉德音) was not on the list after in December last